Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348535 | 0.90 | PPARA (0.52) | PPARACTSSPPARGSYKREN | |
| SCHEMBL2348436 | 0.82 | PPARA (0.53) | PPARACTSSPPARGSYKREN | |
| SCHEMBL2362839 | 0.77 | CTSS (0.48) | PPARACTSSPPARGSYKREN | |
| SCHEMBL2347762 | 0.75 | PPARA (0.47) | PPARACTSSPPARGSYKKLK5 | |
| SCHEMBL14562993 | 0.75 | PPARA (0.50) | PPARACTSSPPARGSYKKLK5 | |
| SCHEMBL3110938 | 0.75 | L3MBTL1 (0.49) | PPARACTSSPPARGSYKMAPT | |
| SCHEMBL13108098 | 0.74 | ATM (0.47) | PPARACTSSKLK5ATMMAPT | |
| SCHEMBL29401143 | 0.74 | PPARA (0.51) | PPARACTSSPPARGMMP9MMP8 | |
| SCHEMBL2350194 | 0.74 | PPARA (0.51) | PPARACTSSPPARGMMP9MMP8 | |
| SCHEMBL3625314 | 0.74 | PPARA (0.45) | PPARACTSSPPARGSYKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | PPARA 1290/4885CTSS 1068/4885PPARG 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.